Watermark

BGB-3111_BGB-A317_Study_001

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-3111_BGB-A317_Study_001

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan